Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Court Rules In Favor Of Viatris For Interchangeable Semglee

Partners Biocon and Viatris To Continue To Market Insulin Glargine Biosimilar

Executive Summary

Viatris and Biocon continue marketing their recently launched interchangeable biosimilar Semglee (insulin glargine-yfgn) as a US appeals court affirms that the challenged claims of five of Sanofi’s Lantus SoloSTAR device patents are unpatentable.

You may also be interested in...



Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar

A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.

Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022.  All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel